Physician epidemiologist and expert consultant. MD, MPH, DrPH. ABPM board certified in Occupational Medicine / Public Health and General Preventive Medicine.
Since its IPO less than two years ago, 60 Degrees Pharmaceuticals $SXTP has lost nearly 99% of its market value. This extraordinary failure may, in part, reflect concerns for the safety of quinoline-based antimalarials in the aftermath of mefloquine’s “black box” warning. 🧵
What does the future hold for $SXTP? A major rally, or a further 99% drop in market value? We shall find out in due course. Follow me for future insights and updates.
Since its IPO less than two years ago, 60 Degrees Pharmaceuticals $SXTP has lost nearly 99% of its market value. This extraordinary failure may, in part, reflect concerns for the safety of quinoline-based antimalarials in the aftermath of mefloquine’s “black box” warning. 🧵
Since its IPO less than two years ago, 60 Degrees Pharmaceuticals $SXTP has lost nearly 99% of its market value. This extraordinary failure may, in part, reflect concerns for the safety of quinoline-based antimalarials in the aftermath of mefloquine’s “black box” warning. 🧵
By way of disclosure, I do not and will not ever hold any positions in $SXTP. This is not investment advice. Do your own research and consult with a professional before making any investment decisions.